Table 1 Laboratory and clinical characteristics of the patients and control subjects included in the study
From: Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis
Characteristics | All SSc (n = 31) | Non-ILD-SSc (n = 10) | SSc-ILD (n = 21) | Other CTD (n = 10) | HC (n = 20) |
|---|---|---|---|---|---|
Age (mean ± SD) | 51 ± 13 | 49 ± 14 | 53 ± 12 | 47 ± 11 | 40 ± 11 |
Female,n(%) | 27 (87) | 10 (91) | 17 (85) | 8 (80) | 17 (85) |
Course of disease (mean ± SD) | 8 ± 7 | 8 ± 8 | 9 ± 8 | NA | |
lSSc/dSSc % | 55/45 | 45/55 | 60/40 | ||
PAH,n(%) | 3 (10) | 0 (0) | 3 (15) | ||
Raynaud’s phenomenon,n(%) | 28 (90) | 9 (82) | 19 (45) | ||
Anti-Scl-70 antibody,n(%) | 13 (42) | 4 (36) | 9 (45) | ||
ANA,n(%) | 30 (97) | 10 (91) | 20 (100) | ||
Anti-RNP,n(%) | 8 (26) | 4 (36) | 4 (20) | ||
Anti-centromere,n(%) | 8 (26) | 2 (18) | 6 (30) | ||
mRSS (mean ± SD)n = 25 | 12 ± 10 | 21 ± 14 | 10 ± 7 | ||
Immunosuppressive therapy ever,n(%) | 11 (35) | 5 (45) | 6 (25) | ||
Cyclophosphamide,n(%) | 6 (19) | 3 (27) | 3 (15) | ||
Methotrexate,n(%) | 2 (6) | 0 (0) | 2 (5) | ||
Mycophenolate mofetil,n(%) | 3 (10) | 2 (18) | 1 (5) | ||
FVC % predicted,n = 17 (mean ± SD) | 74.5 ± 14.2 | 78 ± 8.5 | 75.6 ± 16.2 | ||
DLCO% predicted,n = 8 (mean ± SD) | 74.2 ± 22.3 | 70.9 ± 3.5 | 76.2 ± 27.8 | ||
FEV1/FVC%,n = 17 (mean ± SD) | 85.5 ± 11.6 | 76.2 ± 7.5 | 88.4 ± 11.1 | ||
ESR, mm/h (mean ± SD) | 17.10 ± 11 | 17.80 ± 14.36 | 16.76 ± 9.13 | ||
PLT, 109/L (mean ± SD) | 206 ± 67 | 209.40 ± 79.98 | 204.62 ± 61.60 | ||
MPV, fL (mean ± SD) | 11.95 ± 1.49 | 11.23 ± 1.95 | 10.81 ± 1.24 | ||
PDW, fL (mean ± SD) | 0.22 ± 0.07 | 0.23 ± 0.08 | 0.22 ± 0.07 | ||
PCT, % (mean ± SD) | 31.17 ± 11.13 | 34.69 ± 14.07 | 29.49 ± 9.36 | ||
P-LCR, % (mean ± SD) | 13.47 ± 3.30 | 14.12 ± 4.50 | 13.16 ± 2.63 | ||
RA,n(%) | NA | 1 (10) | NA | ||
ANCA-associated vasculitis,n(%) | 1 (10) | ||||
SLE,n(%) | 2 (20) | ||||
SS,n(%) | 1 (10) | ||||
Dermatomyositis,n(%) | 2 (20) | ||||
Polymyositis,n(%) | 3 (30) | ||||